Top Tweets for #PROteuS
Enjoyed discussing the phase 3 #PROTEUS trial with Matthew Karr, MD, for @CancerNetwrk's Between the Lines.
We covered perioperative apalutamide + ADT in high-risk prostate cancer, PSMA PET, safety, clinical implications, and remaining questions.
▶️ Watch the series: https://t.co/v8brxyZR5G
#ProstateCancer #GUOnc
@MJHLifeSciences @OncoAlert @HemOncFellows @oncodaily
🔱 Proteus — check this out! #Proteus

🔥 New Upcoming Listing 🔥
🚀 GroveX will be listing @PROTEUSCOMPUTE with the trading pair $PRTS/USDT.
📅 25th September 2026
⏰ 09:00 AM UTC
Stay tuned for more updates.
#PRTS #Proteus #Crypto #GroveX #Blockchain #Web3

@armeedeTerre @Stat_20e_ra "Nouvelle innovation"...le #PROTEUS standard 1 est DÉJÀ arrivé au @35eRAP_CDC il y a tout juste un an !
Au fait, où en est la valorisation des 50 VAB T20-13, avec électrification du système et brique IA ?
Another milestone achieved on Proteus™. Quantum-Si has demonstrated sequencing with detection of 18 amino acids using a developmental kit run on integrated Proteus instruments.
Read the full PR here: https://t.co/baPadrWaU7
$QSI #Proteus #Proteomcis #SingleMolecule

@RKSayyid @UAUrology and @zklaassen_md @GACancerCenter review #PROTEUS, a phase 3 trial of perioperative apalutamide + ADT vs placebo + ADT in 2,109 patients with high‑risk localized/locally advanced #PCa undergoing radical prostatectomy. Both dual primary endpoints were met: pathologic complete response/minimal residual disease occurred in 8.9% vs 1%, and metastasis‑free survival showed a hazard ratio of 0.80; event‑free survival HR was 0.71, and time to first subsequent therapy was delayed by a median of 6 years. Testosterone recovery was not significantly prolonged with apalutamide added to ADT. #WatchNow in this UroToday #JournalClub discussion > https://t.co/CO6jfOVyJt
🔹 Median follow-up: 60 mo
🔹 5-yr BCR-FS: 44%
🔹 5-yr MFS: 71%
🔹 5-yr CSS: 92%
Providing a real-world benchmark to contextualize perioperative treatment strategies in this high-risk population.
📄 https://t.co/NyszMg9uCA
#ProstateCancer #PROTEUS #Urology
Simulación de Diseño Circuito Timmers (Temporizador) Astable con IC 555, configuración de tiempos mediante componentes Resistivos y Capacitivos, Diseñado y Simulado en #Proteus #Electronica #Simulacion #Circuitos #Digital #Analogico #Frecuencia #Logico #Osciloscopio
+Info al DM
Asesorías y Resolución Ejercicios en Diseños de Electrónica / Circuitos Eléctricos, Automatismos.
Simulación en #Proteus #Multisim, #Fluidsim, #CADEsimu, #Tinkercad, #Arduino, entre otros.
+Info https://t.co/Z4nQxTBcrp
#Electronica #Circuitos #Automatizacion

🌟 PROTEUS en español. @LosUromigos
Muy recomendable para colegas de habla hispana interesados en cáncer de próstata de alto riesgo y oncología genitourinaria.
@brian_rini @tompowles1 @NehaVapiwala
Más allá de los resultados, #PROTEUS abre preguntas clínicas muy relevantes:
🔹 ¿Cómo interpretar MFS y respuesta patológica en este contexto?
🔹 ¿A qué pacientes podría aplicar una estrategia perioperatoria?
🔹 ¿Cómo contextualizar el brazo control?
🔹 ¿Cómo integrar estos datos en la discusión entre oncología médica, urología y radioterapia?
🔹 ¿Qué preguntas siguen abiertas para la práctica diaria?
El valor del episodio está en escuchar una conversación experta sobre datos, matices y controversias.
@OncoAlert @_SEOM @sogug1 @SEOR_ESP @GuardConsortium @SMEOMX @SChOncologia @achoHematoYOnco @oncologiaec @SP_Cancerologia @SOMPU_onco @ASCO @myESMO @uroweb
#LosUromigos #GUOnc #ProstateCancer #Oncologia #RadOnc #UroOnc #MedEd
🎙️ Nuevo episodio de #LosUromigos en español.
¿Cambia PROTEUS la práctica en cáncer de próstata de alto riesgo?
@brian_rini y @tompowles1 conversan con @NehaVapiwala sobre los puntos más controvertidos del estudio:
📌 MFS vs respuesta patológica
📌 Selección de pacientes
📌 Brazo control
📌 Cirugía vs radioterapia + tratamiento sistémico
🎧 Ya disponible en español.
🔗https://t.co/ICEmkLVcKG
@OncoAlert @Uromigos @_SEOM @SauUrologia @SMEOMX

Day 2 | Maker Internship Program 2026 ⚡
A more hands-on day using Proteus to simulate:
• BJT as Amplifier & Switch
• Half/Full-Wave Rectifiers
• Op-Amp applications: Comparator, Addition, Subtraction, Integration & Differentiation.
#Electronics #Proteus

Why is everyone talking about the PROTEUS trial?
In the latest episode of the Uromigos Podcast, Dr. Neha Vapiwala joined the Uromigos to discuss the PROTEUS trial, what the findings mean, and where the conversation goes from
here.
🎧 Listen to the full episode: https://t.co/eXtj8Z74KD

@RKSayyid @UAUrology and @zklaassen_md @GACancerCenter review #PROTEUS, a phase 3 trial of perioperative apalutamide + ADT vs placebo + ADT in 2,109 patients with high‑risk localized/locally advanced #PCa undergoing radical prostatectomy. Both dual primary endpoints were met: pathologic complete response/minimal residual disease occurred in 8.9% vs 1%, and metastasis‑free survival showed a hazard ratio of 0.80; event‑free survival HR was 0.71, and time to first subsequent therapy was delayed by a median of 6 years. Testosterone recovery was not significantly prolonged with apalutamide added to ADT. #WatchNow in this UroToday #JournalClub discussion > https://t.co/CO6jfOVyJt
#proteus get together

Point-Counterpoint: Neoadjuvant intensified ADT-radical prostatectomy needs more validation.
Key cautions from Dr. Evan Yu @fredhutch at #USPCC26 on #PROTEUS:
⚠️ Primary MFS benefit relied heavily on PSMA PET (53% of events); conventional imaging MFS was NOT significant
⚠️ ICECaP validated MFS→OS using conventional imaging—not PSMA PET. PSMA-detected progression may behave more like BCR, not true metastatic disease
⚠️ Control arm included ~1 year of ADT; current surgical SOC is RP alone. True toxicity burden (metabolic, CV, sexual, QoL) is underestimated
⚠️ Mature SOC exists for many: RT + long-term ADT (EORTC) and RT + ADT + abiraterone (STAMPEDE) with proven OS benefit
⏳ Await PROTEUS substudy (APA + RP vs RP alone) and longer follow-up before adopting widely
Bottom line: Discuss with patients, but don't declare a new standard yet—more validation needed.
Written coverage by @zklaassen_md @GACancerCenter > https://t.co/XCZRxF414C @PCFnews @neerajaiims

Point-Counterpoint: Does #PROTEUS represents a new standard of care?
Dr. David Morris @UA_Nashville at #USPCC26 says YES—for carefully selected patients planning RP.
Key arguments:
✅ PSMA PET is now routine practice—MFS by PSMA PET reflects real-world staging
✅ Perioperative apalutamide delayed next therapy by ~3 years (NNT ~10 at 5 yrs)
✅ ~3× higher odds of organ-confined disease; pCR may convert some to surgical candidates
✅ 77–80% recover testosterone >150 ng/dL by 1 year with proactive AE management
Bottom line: For high-risk/node+ patients accepting upfront toxicity to delay progression, PROTEUS supports perioperative intensified therapy as "a" new SOC.
Written coverage by @zklaassen_md @GACancerCenter > https://t.co/agXcd2Kw3N

Alerta microbiológica: #Proteus mirabilis portador de blaOXA-23, una #carbapenemasa habitualmente asociada a #Acinetobacter baumannii
La expansión interespecie de mecanismos de resistencia recuerda que la vigilancia genómica sigue siendo esencial
#AMR
DOI:10.3201/eid3208.260588

Last Seen Hashtags on Sotwe
극네토
Seen from Korea
kentekenplaat
Seen from United States
mydadsbiggerthnayourdad
Seen from United States
反差
eroticprincess
Seen from United States
Maharashtra Accountability
Seen from Singapore
monkeyapp
Seen from Thailand
domingoxxvordinarioa
Seen from United States
opticalDCI
Seen from United States
minichat()**filter:native_video()**filter:native_video()**filter:native_video()**filter:native_video
Seen from Italy
Trends for you
Most Popular Users

Elon Musk 
@elonmusk
241.7M followers

Barack Obama 
@barackobama
119M followers

Cristiano Ronaldo 
@cristiano
114.4M followers

Donald J. Trump 
@realdonaldtrump
111.9M followers

Narendra Modi 
@narendramodi
107.2M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.4M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
84M followers

Lady Gaga 
@ladygaga
75.4M followers

Virat Kohli 
@imvkohli
73.4M followers

Kim Kardashian 
@kimkardashian
70.9M followers

YouTube 
@youtube
68.8M followers

Neymar Jr 
@neymarjr
66.4M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63.1M followers

The Ellen Show
@theellenshow
62.3M followers

CNN 
@cnn
61.8M followers

X 
@x
60.7M followers




































